Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Open accessAbstract
BACKGROUND: Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1-2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy. METHODS: In part 1, the dose-escalation phase, we administered daratumumab at doses of 0.005 to 24 mg per kilogram of body weight. In part 2, the dose-expansion phase, 30 patients received 8 mg per kilogram of daratumumab and 42 received 16 mg per kilogram, administered once weekly (8 doses), twice monthly (8 doses), and monthly for up to 24 months. End points included safety, efficacy, and pharmacokinetics. RESULTS: No maximum tolerated dose was identified in part 1. In part 2, the median time since diagnosis was 5.7 years. Patients had received a median of four prior treatments; 79% of the patients had disease that was refractory to the last therapy received (64% had disease refractory to proteasome inhibitors and immunomodulatory drugs and 64% had disease refractory to bortezomib and lenalidomide), and 76% had received autologous stem-cell transplants. Infusion-related reactions in part 2 were mild (71% of patients had an event of any grade, and 1% had an event of grade 3), with no dose-dependent adverse events. The most common adverse events of grade 3 or 4 (in ≥ 5% of patients) were pneumonia and thrombocytopenia. The overall response rate was 36% in the cohort that received 16 mg per kilogram (15 patients had a partial response or better, including 2 with a complete response and 2 with a very good partial response) and 10% in the cohort that received 8 mg per kilogram (3 had a partial response). In the cohort that received 16 mg per kilogram, the median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2 to 8.1), and 65% (95% CI, 28 to 86) of the patients who had a response did not have progression at 12 months. CONCLUSIONS: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma. (Funded by Janssen Research and Development and Genmab; ClinicalTrials.gov number, NCT00574288.).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Daratumumab has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [10]
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredElotuzumab targets SLAMF7, while daratumumab and isatuximab target CD38.
“Elotuzumab targets SLAMF7; daratumumab and isatuximab target CD38 respectively.84–87”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [85]
Daratumumab is active in relapsed, refractory multiple myeloma.
“Daratumumab is active in relapsed, refractory multiple myeloma.85”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [85]
After the implementation of guidelines from other studies of daratumumab regarding the management of infusion-related reactions, infusion-related reactions were consistent with daratumumab monotherapy and combination therapy, were mostly of grade 1 or 2, and usually occurred during the first infusion.
“After the implementation of guidelines from other studies of daratumumab regarding the management of infusion-related reactions, infusion-related reactions were consistent with daratumumab monotherapy 9,10 and combination therapy, 18,19,32 were mostly of grade 1 or 2, and usually occurred during the first infusion.”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [10]
Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone and of daratumumab.
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,238 · see citing works
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322 · see citing works
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037 · see citing works
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036 · see citing works
Self-citationKumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721 · see citing works
Self-citationSiegel, D. S. D., Martin, T. G., Wang, M. L., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 656 · see citing works
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521 · see citing works
Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma
Lin, P. Y., Owens, R., Tricot, G. J. K., & Wilson, C. S. (2004) · American Journal of Clinical Pathology · doi:10.1309/74r4tb90buwh27jx · Cited by 454 · see citing works
Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381 · see citing works
Self-citationZonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342 · see citing works
Deckert, J., Wetzel, M.-C., Bartle, L. M., Skaletskaya, A., Goldmacher, V. S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0695 · Cited by 333 · see citing works
Lammerts van Bueren, J., Jakobs, D., Kaldenhoven, N., Roza, M., Hiddingh, S., Meesters, J., Voorhorst, M., Gresnigt, E., Wiegman, L., Ortiz Buijsse, A., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3474.3474 · Cited by 222 · see citing works
Richardson, P. G. G., Baz, R., Wang, M. L., Jakubowiak, A. J., Laubach, J. P., Harvey, R. D., Talpaz, M., Berg, D. T., Liu, G., Jiang, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548826 · Cited by 202 · see citing works
Self-citationNijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1813 · Cited by 151 · see citing works
Self-citationMráz, M., Chen, L., Rassenti, L. Z., Ghia, E. M., Li, H., Jepsen, K., Smith, E. N., Messer, K. S., Frazer, K. A., & Kipps, T. J. (2014) · Blood · doi:10.1182/blood-2013-09-527234 · Cited by 146 · see citing works
Rajkumar, S. V., Harousseau, J., Durie, B. G. M., Anderson, K. C., Dimopoulos, M. A., Kyle, R. A., Bladé, J., Richardson, P. G. G., Orlowski, R. Z., Siegel, D. S. D., et al. (2011) · Institutional Research Information System University of Turin (University of Turin) · Cited by 131 · see citing works
Self-citationCD38/CD19: a lipid raft–dependent signaling complex in human B cells
Deaglio, S., Vaisitti, T., Billington, R. A., Bergui, L., Omedè, P., Genazzani, A. A., & Malavasi, F. (2007) · Blood · doi:10.1182/blood-2006-12-061812 · Cited by 118 · see citing works
Interference of Monoclonal Antibody Therapies with Serum Protein Electrophoresis Tests
McCudden, C. R., Voorhees, P. M., Hainsworth, S. A., Whinna, H. C., Chapman, J., Hammett‐Stabler, C. A., & Willis, M. S. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.152116 · Cited by 76 · see citing works
Current strategies for treatment of relapsed/refractory multiple myeloma
Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A. J., Lonial, S., & Richardson, P. G. G. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882764 · Cited by 67 · see citing works
Self-citationSantonocito, A., Consoli, U., Bagnato, S., Milone, G., Palumbo, G. A., Raimondo, F. D., Stagno, F., Guglielmo, P., & Giustolisi, R. (2003) · Leukemia Research · doi:10.1016/j.leukres.2003.09.015 · Cited by 61 · see citing works
Martin, T. G., Hsu, K., Strickland, S. A., Glenn, M. J., Mikhael, J. R., & Charpentier, E. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8532 · Cited by 49 · see citing works
Plesner, T., Arkenau, H., Lokhorst, H. M., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M. C., Lassen, U., Laubach, J. P., Ahmadi, T., et al. (2014) · Blood · doi:10.1182/blood.v124.21.84.84 · Cited by 49 · see citing works
Self-citationMartin, T. G., Baz, R., Benson, D. M., Lendvai, N. K., Campana, F., Charpentier, E., & Vij, R. (2014) · Blood · doi:10.1182/blood.v124.21.83.83 · Cited by 38 · see citing works
Konopleva, M. Y., Estrov, Z. E., Zhao, S., Andreeff, M., & Mehta, K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4702 · Cited by 34 · see citing works
Richardson, P. G. G., Jagannath, S., Moreau, P., Jakubowiak, A. J., Raab, M. S., Facon, T. T. F., Vij, R., White, D. J., Reece, D. E., Benboubker, L., et al. (2014) · Blood · doi:10.1182/blood.v124.21.302.302 · Cited by 34 · see citing works
Self-citationResponsibility for Costs Associated With Clinical Trials
Martin, P. J., Davenport-Ennis, N., Petrelli, N. J., Stewart, F. M., Appelbaum, F. R., & Benson, A. B. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1422 · Cited by 26 · see citing works
Axel, A. E., McCudden, C. R., Xie, H., Hall, B. M., & Sasser, A. K. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-2563 · Cited by 22 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [9]9. killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-8.
Cited by
Sorted by citations
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522 · see citing works
Self-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · see citing works
Self-citationLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257 · see citing works
Self-citationKumar, S. K., Rajkumar, S. V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,235 · see citing works
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,027 · see citing works
Self-citationGuidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdiş, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 982 · see citing works
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B. M. P., Bald, J., Plesner, T., Syed, K. W., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 961 · see citing works
Self-citationvan de Donk, N. W. C. J., Pawlyn, C., & Yong, K. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 892 · see citing works
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · see citing works
Self-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 802 · see citing works
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883 · see citing works
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744 · see citing works
Self-citationVoorhees, P. M., Kaufman, J. L., Laubach, J. P., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R. W., Costa, L. J., Anderson, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020005288 · Cited by 698 · see citing works
Self-citationAntiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K. E. B., Dupuis, L. L., Dusetzina, S. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4789 · Cited by 634 · see citing works
Genomic complexity of multiple myeloma and its clinical implications
Manier, S., Salem, K. Z., Park, J., Landau, D. A., Getz, G. A., & Ghobrial, I. M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.122 · Cited by 552 · see citing works
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534 · see citing works
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531 · see citing works
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Kumar, S. K., Kaufman, J. L., Gasparetto, C., Mikhael, J. R., Vij, R., Pegourié, B., Benboubker, L., Facon, T. T. F., Amiot, M., Moreau, P., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788786 · Cited by 526 · see citing works
Zhao, W., Liu, J., Wang, B., Chen, Y., Cao, X.-M., Yang, Y., Zhang, Y., Wang, F., Zhang, P., Lei, B., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0681-6 · Cited by 520 · see citing works
Self-citationCD38 antibodies in multiple myeloma: back to the future
van de Donk, N. W. C. J., Richardson, P. G. G., & Malavasi, F. (2017) · Blood · doi:10.1182/blood-2017-06-740944 · Cited by 495 · see citing works
Self-citationImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 483 · see citing works
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462 · see citing works
Self-citationPD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Goodman, A. M., Patel, S. P., & Kurzrock, R. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.168 · Cited by 457 · see citing works
Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 460 · see citing works
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Chari, A., Suvannasankha, A., Fay, J. W., Arnulf, B., Kaufman, J. L., Ifthikharuddin, J. J., Weiss, B. M., Krishnan, A. Y., Lentzsch, S., Comenzo, R. L., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785246 · Cited by 444 · see citing works
Self-citationComplement in cancer: untangling an intricate relationship
Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A., & Lambris, J. D. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.97 · Cited by 427 · see citing works
Usmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407 · see citing works
Self-citationNijhof, I. S., Casneuf, T., van Velzen, J. F., van Kessel, B., Axel, A. E., Syed, K. W., Groen, R. W. J., van Duin, M., Sonneveld, P., Minnema, M. C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-703439 · Cited by 393 · see citing works
Self-citationCD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
van de Donk, N. W. C. J., & Usmani, S. Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02134 · Cited by 357 · see citing works
Monoclonal antibodies targeting <scp>CD</scp>38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353 · see citing works
Self-citationB cells in the pathogenesis of primary Sjögren syndrome
Nocturne, G., & Mariette, X. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2018.1 · Cited by 361 · see citing works
Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.138 · Cited by 351 · see citing works
Self-citationTai, Y., Acharya, C., An, G., Moschetta, M., Zhong, M. Y., Feng, X., Cea, M., Cagnetta, A., Wen, K., van Eenennaam, H., et al. (2016) · Blood · doi:10.1182/blood-2016-01-691162 · Cited by 352 · see citing works
Self-citationThe Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases
Hogan, K. A., Chini, C. C. S., & Chini, E. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01187 · Cited by 337 · see citing works
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus
Ostendorf, L., Burns, M., Durek, P., Heinz, G. A., Heinrich, F., Garantziotis, P., Enghard, P., Richter, U., Biesen, R., Schneider, U., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2023325 · Cited by 339 · see citing works
Seckinger, A., Delgado, J. A., Moser, S., Moreno, L., Neuber, B., Grab, A. L., Lipp, S., Merino, J., Prósper, F., Emde, M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.002 · Cited by 313 · see citing works
Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., & Anderson, K. C. (2018) · Leukemia · doi:10.1038/leu.2017.329 · Cited by 305 · see citing works
Self-citationThe tumor microenvironment in esophageal cancer
Lin, E. W., Karakasheva, T. A., Hicks, P. D., Bass, A. J., & Rustgi, A. K. (2016) · Oncogene · doi:10.1038/onc.2016.34 · Cited by 298 · see citing works
Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501351 · Cited by 297 · see citing works
Spencer, A. G., Lentzsch, S., Weisel, K. C., Avet‐Loiseau, H., Mark, T. M., Špıčka, I., Masszi, T., Lauri, B., Levin, M., Bosi, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194118 · Cited by 269 · see citing works
Self-citationCD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma
Marlein, C. R., Piddock, R. E., Mistry, J. J., Zaitseva, L., Hellmich, C., Horton, R. H., Zhou, Z., Auger, M. J., Bowles, K. M., & Rushworth, S. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0773 · Cited by 266 · see citing works
Mateos, M., Nahi, H., Legiec, W. M., Grosicki, S., Vorobyev, V. I., Špıčka, I., Hungria, V., Korenkova, S., Bahlis, N. J., Flogegård, M., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30070-3 · Cited by 259 · see citing works
Self-citationImmunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 258 · see citing works
Feng, X., Zhang, L., Acharya, C., An, G., Wen, K., Qiu, L., Munshi, N. C., Tai, Y., & Anderson, K. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3192 · Cited by 252 · see citing works
Trudel, S., Lendvai, N. K., Popat, R., Voorhees, P. M., Reeves, B., Libby, E. N., Richardson, P. G. G., Anderson, L. D., Sutherland, H. J., Yong, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30576-x · Cited by 251 · see citing works
Self-citationBCMA-targeted immunotherapy for multiple myeloma
Yu, B., Jiang, T., & Liu, D. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00962-7 · Cited by 243 · see citing works
Casneuf, T., Xu, X. S., Adams, H., Axel, A. E., Chiu, C. W., Khan, I., Ahmadi, T., Yan, X., Lonial, S., Plesner, T., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006866 · Cited by 231 · see citing works
Self-citationMultiple Myeloma: Available Therapies and Causes of Drug Resistance
Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 233 · see citing works
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
Bride, K. L., Vincent, T. L., Im, S.-Y., Aplenc, R., Barrett, D. M., Carroll, W. L., Carson, R. L., Dai, Y. E., Devidas, M., Dunsmore, K. P., et al. (2018) · Blood · doi:10.1182/blood-2017-07-794214 · Cited by 229 · see citing works
The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging
Chini, E. N., Chini, C. C. S., Espindola Netto, J. M., de Oliveira, G. C., & van Schooten, W. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.02.001 · Cited by 227 · see citing works
Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., & Liedtke, M. (2017) · Blood · doi:10.1182/blood-2017-01-763599 · Cited by 226 · see citing works
Shah, N. D., Li, L., McCarty, J. M., Kaur, I., Yvon, E. S., Shaim, H., Müftüoğlu, M., Liu, E., Orlowski, R. Z., Cooper, L. J. N., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14570 · Cited by 218 · see citing works
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Moreno, L., Pérez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., Rodríguez, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1597 · Cited by 221 · see citing works
Otani, I. M., Lehman, H. K., Jongco, A. M., Tsao, L. R., Azar, A., Tarrant, T. K., Engel, E. R., Walter, J. E., Truong, T. Q., Khan, D. A., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.01.025 · Cited by 214 · see citing works
Trudel, S., Lendvai, N. K., Popat, R., Voorhees, P. M., Reeves, B., Libby, E. N., Richardson, P. G. G., Hoos, A., Gupta, I. V., Bragulat, V., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0196-6 · Cited by 213 · see citing works
Self-citationNAD and the aging process: role in life, death and everything in between
Chini, C. C. S., Tarragó, M. G., & Chini, E. N. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.11.003 · Cited by 208 · see citing works
Chimeric antigen receptor T-cell therapies for multiple myeloma
Mikkilineni, L., & Kochenderfer, J. N. (2017) · Blood · doi:10.1182/blood-2017-06-793869 · Cited by 213 · see citing works
Palladini, G. O., Kastritis, E., Maurer, M. S., Zonder, J. A., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Bumma, N., Kaufman, J. L., et al. (2020) · Blood · doi:10.1182/blood.2019004460 · Cited by 212 · see citing works
Self-citationPlasma cells as an innovative target in autoimmune disease with renal manifestations
Hiepe, F., & Radbruch, A. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.20 · Cited by 210 · see citing works
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 217 · see citing works
Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis
Griffin, J. M., Rosenblum, H., & Maurer, M. S. (2021) · Circulation Research · doi:10.1161/circresaha.121.318187 · Cited by 216 · see citing works
Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., et al. (2018) · Leukemia · doi:10.1038/leu.2017.211 · Cited by 200 · see citing works
Self-citationvan de Donk, N. W. C. J., Moreau, P., Plesner, T., Palumbo, A. P., Gay, F., Laubach, J. P., Malavasi, F., Avet‐Loiseau, H., Mateos, M., Sonneveld, P., et al. (2015) · Blood · doi:10.1182/blood-2015-10-646810 · Cited by 204 · see citing works
Self-citationA bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Mei, H., Li, C., Jiang, H., Zhao, X., Huang, Z., Jin, D., Guo, T., Kou, H., Liu, L., Tang, L., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01170-7 · Cited by 222 · see citing works
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
del Valle, A. S., Anel, A., Naval, J., & Marzo, I. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00050 · Cited by 196 · see citing works
Drent, E., Groen, R. W. J., Noort, W. A., Themeli, M., van Bueren, J. J. L., Parren, P. W. H. I., Kuball, J. H. E., Sebestyén, Z., Yuan, H., de Bruijn, J. D., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.137620 · Cited by 186 · see citing works
Self-citationDahlberg, C. I. M., Sarhan, D., Chrobok, M., Duru, A. D., & Alici, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00605 · Cited by 183 · see citing works
Multiple myeloma in the marrow: pathogenesis and treatments
Fairfield, H. E., Falank, C. R., Avery, L. M., & Reagan, M. R. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13038 · Cited by 188 · see citing works
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
An, G., Acharya, C., Feng, X., Wen, K., Zhong, M., Zhang, L., Munshi, N. C., Qiu, L., Tai, Y., & Anderson, K. C. (2016) · Blood · doi:10.1182/blood-2016-03-707547 · Cited by 184 · see citing works
Novel agents in the treatment of multiple myeloma: a review about the future
Naymagon, L., & Abdul‐Hay, M. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0282-1 · Cited by 177 · see citing works
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
Sanchez, L. J., Wang, Y., Siegel, D. S. D., & Wang, M. L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0283-0 · Cited by 178 · see citing works
Krejcik, J., Frerichs, K. A., Nijhof, I. S., van Kessel, B., van Velzen, J. F., Bloem, A. C., Broekmans, M. E. C., Zweegman, S., van Meerloo, J., Musters, R. J. P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2027 · Cited by 175 · see citing works
Self-citationProgress and Paradigms in Multiple Myeloma
Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0625 · Cited by 171 · see citing works
Very-large-scale production of antibodies in plants: The biologization of manufacturing
Buyel, J. F., Twyman, R. M., & Fischer, R. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.03.011 · Cited by 168 · see citing works
Daratumumab in multiple myeloma
Nooka, A. K., Kaufman, J. L., Hofmeister, C. C., Joseph, N. S., Heffner, T. L., Gupta, V. A., Sullivan, H. C., Neish, A. S., Dhodapkar, M. V., & Lonial, S. (2019) · Cancer · doi:10.1002/cncr.32065 · Cited by 166 · see citing works
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 171 · see citing works
Adams, H., Stevenaert, F., Krejcik, J., der Borght, K. V., Smets, T., Bald, J., Abraham, Y., Ceulemans, H., Chiu, C. W., Vanhoof, G., et al. (2018) · Cytometry Part A · doi:10.1002/cyto.a.23693 · Cited by 163 · see citing works
Self-citationMultiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljević, M., Baz, R., Campagnaro, E. L., Castillo, J. J., Costello, C. L., D'Angelo, C. R., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0061 · Cited by 169 · see citing works
Emerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 157 · see citing works
Dimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J. R., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00223-1 · Cited by 168 · see citing works
Self-citationSecond primary malignancies in multiple myeloma: an overview and IMWG consensus
Musto, P., Anderson, K. C., Attal, M., Richardson, P. G. G., Badros, A., Hou, J., Comenzo, R. L., Du, J., Durie, B. G. M., Miguel, J. F. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw606 · Cited by 153 · see citing works
Self-citationHu, Y., Li, J., Ni, F., Yang, Z., Gui, X., Bao, Z., Zhao, H., Wei, G., Wang, Y., Zhang, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32960-3 · Cited by 155 · see citing works
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Paiva, B., Cedena, M., Puig, N., Arana, P., Vídriales, M., Cordón, L., Flores-Montero, J. A., Gutierrez, N. C., Martín-Ramos, M.-L., Martínez‐López, J., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705319 · Cited by 150 · see citing works
Nanomedicines for the treatment of hematological malignancies
Deshantri, A. K., Varela-Moreira, A., Ecker, V., Mandhane, S. N., Schiffelers, R. M., Buchner, M., & Fens, M. H. A. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.034 · Cited by 147 · see citing works
Pillarisetti, K., Powers, G., Luistro, L., Babich, A., Baldwin, E., Li, Y., Zhang, X., Mendonça, M., Majewski, N., Nanjunda, R., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002393 · Cited by 144 · see citing works
“Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape of myeloma management, leading to improved disease control and prolonged survival.(3-12) Despite these therapeutic advances, nearly all patients will eventually relapse”
BackgroundTherapy for Relapsed Multiple Myeloma
Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A. A., Fonseca, R., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Kapoor, P., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.003 · Cited by 140 · see citing works
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Robak, P. J., & Robak, T. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0269-9 · Cited by 141 · see citing works
Co-evolution of tumor and immune cells during progression of multiple myeloma
Liu, R., Gao, Q., Foltz, S. M., Fowles, J. S., Yao, L., Wang, J. T., Cao, S., Sun, H., Wendl, M. C., Sethuraman, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22804-x · Cited by 132 · see citing works
Self-citationMoreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., Zweegman, S., Caillon, H., Caillot, D., Avet‐Loiseau, H., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00282-1 · Cited by 140 · see citing works
Self-citationCole, S., Walsh, A. M., Yin, X., Wechalekar, M. D., Smith, M., Proudman, S., Veale, D. J., Fearon, U., Pitzalis, C., Humby, F., et al. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1578-z · Cited by 133 · see citing works
Avet‐Loiseau, H., Ludwig, H., Landgren, O., Paiva, B., Morris, C., Yang, H., Zhou, K., Ro, S. K., & Mateos, M. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.622 · Cited by 130 · see citing works
Zuch de Zafra, C. L., Fajardo, F., Zhong, W., Bernett, M. J., Muchhal, U. S., Moore, G. L., Stevens, J., Case, R., Pearson, J. T., Liu, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2752 · Cited by 132 · see citing works
“org Clin Cancer Res; 25(13) July 1, 2019 3923”
BackgroundInfluentialRoussel, M., Merlini, G., Chevret, S., Arnulf, B., Stoppa, A. M., Perrot, A., Palladini, G. O., Karlin, L., Royer, B., Huart, A., et al. (2020) · Blood · doi:10.1182/blood.2019004369 · Cited by 131 · see citing works
Altaner, Č. (2008) · PubMed · Cited by 130 · see citing works
Facon, T. T. F., Cook, G., Usmani, S. Z., Hulin, C., Kumar, S. K., Plesner, T., Touzeau, C., Bahlis, N. J., Basu, S., Nahi, H., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01488-8 · Cited by 129 · see citing works
Self-citationZhao, Y., Dong, Q., Li, J., Zhang, K., Qin, J., Zhao, J., Sun, Q., Wang, Z., Wartmann, T., Jauch, K. W., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.08.002 · Cited by 126 · see citing works
McCudden, C. R., Axel, A. E., Slaets, D., Dejoie, T., Clemens, P. L., Frans, S., Bald, J., Plesner, T., Jacobs, J. F. M., van de Donk, N. W. C. J., et al. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1031 · Cited by 125 · see citing works
Self-citationWang, Y., Zhang, Y., Hughes, T. L., Zhang, J., Caligiuri, M. A., Benson, D. M., & Yu, J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3117 · Cited by 124 · see citing works
Casneuf, T., Adams, H., van de Donk, N. W. C. J., Abraham, Y., Bald, J., Vanhoof, G., der Borght, K. V., Smets, T., Foulk, B., Nielsen, K. C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0855-4 · Cited by 123 · see citing works
Self-citationmTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion
Liu, H.-J., Du, H., Khabibullin, D., Zarei, M., Wei, K., Freeman, G. J., Kwiatkowski, D. J., & Henske, E. P. (2023) · Nature Communications · doi:10.1038/s41467-023-36881-7 · Cited by 123 · see citing works
- Authors
- Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N. W. C. J., Ahmadi, T., Khan, I., Uhlar, C. M., Wang, J., Sasser, A. K., Losic, N., Lisby, S., Basse, L., Brun, N., & Richardson, P. G.
- Affiliations
- University of Copenhagen (DK)
- University of Southern Denmark (DK)
- Harvard University (US)
- Karolinska University Hospital (SE)
- Lund University (SE)
- University Medical Center Utrecht (NL)
- University of Turin (IT)
- Janssen Research & Development (United States) (US)
- Genmab (Denmark) (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-09-24
- Volume
- 373
- Issue
- 13
- Pages
- 1207-1219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1902692042
- Semantic Scholar
- c731f1036338cb22a95a42420cb4ccf650d6c359
- Cited by
- 1,117
- References
- 27
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 63 · 2023: 87 · 2022: 83 · 2021: 134 · 2020: 131 · 2019: 108 · 2018: 129 · 2017: 125 · 2016: 143 · 2015: 14
- FWCI
- 107.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, daratumumab, CD38, monoclonal antibodies, relapsed/refractory multiple myeloma, monotherapy, dose escalation, progression-free survival, overall response rate, infusion reactions, pharmacokinetics, autologous stem cell transplantation, lenalidomide-refractory disease, bortezomib-refractory disease, pneumonia, thrombocytopenia, complete response, very good partial response
- MeSH terms
- Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Multiple Myeloma, Pneumonia, Thrombocytopenia, Disease-Free Survival, Drug Resistance, Neoplasm, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
